The Role of Toll-Like Receptors in Diabetes-Induced Inflammation: Implications for Vascular Complications

Overview

Journal Curr Diab Rep

Publisher Current Science

Specialty Endocrinology

Date 2012 Feb 9

PMID 22314791

Citations 32

Authors

Ishwarlal Jialal

Harmeet Kaur

Affiliations

Soon will be listed here.

Abstract

Diabetes confers an increased risk for both microvascular and macrovascular complications. Numerous studies have reported increased levels of biomarkers of inflammation that could predispose to vascular complications. The pattern recognition receptors of the innate immune response, such as Toll-like receptors (TLRs), especially TLR2 and TLR4, have been incriminated in both atherosclerosis and insulin resistance. Studies have reported increased expression and activity of these receptors in both type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus. Most recently, knockout of TLR2 has been shown to attenuate the proinflammatory state of T1DM and the progression of diabetic nephropathy. The increased activity of TLRs in diabetes could be the result of a conspiracy of both endogenous and exogenous ligands. Biomediators of increased TLR2 and TLR4 activity include tumor necrosis factor-α, interleukin (IL)-1β, IL-6, monocyte chemoattractant protein-1, and type 1 interferons. Modulating these TLRs could be beneficial in forestalling diabetic complications given the pivotal role of inflammation in both microvascular and macrovascular complications.

Citing Articles

Benefits of Cilostazol's Effect on Vascular and Neuropathic Complications Caused by Diabetes.

Musial D, Ajita M, Bomfim G Med Sci (Basel). 2025; 13(1.

PMID: 39846696 PMC: 11755643. DOI: 10.3390/medsci13010001.

The role of innate immunity in diabetic nephropathy and their therapeutic consequences.

Yang M, Zhang C J Pharm Anal. 2024; 14(1):39-51.

PMID: 38352948 PMC: 10859537. DOI: 10.1016/j.jpha.2023.09.003.

Toll-like Receptors as Pro-Thrombotic Drivers in Viral Infections: A Narrative Review.

Panzer B, Kopp C, Neumayer C, Koppensteiner R, Jozkowicz A, Poledniczek M Cells. 2023; 12(14).

PMID: 37508529 PMC: 10377790. DOI: 10.3390/cells12141865.

Effect of Immunomodulating Extract and Some Isolates from A.D. Poulsen Fruits on Diabetic Patients with Tuberculosis.

Ilyas Y M, Sahidin I, Jabbar A, Yodha A, Diantini A, Pradipta I Molecules. 2023; 28(5).

PMID: 36903646 PMC: 10005397. DOI: 10.3390/molecules28052401.

Silencing TLR4 using an ultrasound-targeted microbubble destruction-based shRNA system reduces ischemia-induced seizures in hyperglycemic rats.

Chen J, Huang F, Fang X, Li S, Liang Y Open Life Sci. 2023; 17(1):1689-1697.

PMID: 36619717 PMC: 9795576. DOI: 10.1515/biol-2022-0526.

References

Dasu M, Devaraj S, Zhao L, Hwang D, Jialal I . High glucose induces toll-like receptor expression in human monocytes: mechanism of activation. Diabetes. 2008; 57(11):3090-8. PMC: 2570406. DOI: 10.2337/db08-0564. View

Devaraj S, Dasu M, Park S, Jialal I . Increased levels of ligands of Toll-like receptors 2 and 4 in type 1 diabetes. Diabetologia. 2009; 52(8):1665-8. PMC: 2709882. DOI: 10.1007/s00125-009-1394-8. View

ONeill L . How Toll-like receptors signal: what we know and what we don't know. Curr Opin Immunol. 2005; 18(1):3-9. DOI: 10.1016/j.coi.2005.11.012. View

Dasu M, Park S, Devaraj S, Jialal I . Pioglitazone inhibits Toll-like receptor expression and activity in human monocytes and db/db mice. Endocrinology. 2009; 150(8):3457-64. PMC: 2717888. DOI: 10.1210/en.2008-1757. View

Kawai T, Akira S . The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010; 11(5):373-84. DOI: 10.1038/ni.1863. View

Haffner S, Lehto S, Ronnemaa T, Pyorala K, Laakso M . Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339(4):229-34. DOI: 10.1056/NEJM199807233390404. View

Gurley C, Nichols J, Liu S, Phulwani N, Esen N, Kielian T . Microglia and Astrocyte Activation by Toll-Like Receptor Ligands: Modulation by PPAR-gamma Agonists. PPAR Res. 2008; 2008:453120. PMC: 2435222. DOI: 10.1155/2008/453120. View

Jain S, Kannan K, Lim G, Matthews-Greer J, Mcvie R, Bocchini Jr J . Elevated blood interleukin-6 levels in hyperketonemic type 1 diabetic patients and secretion by acetoacetate-treated cultured U937 monocytes. Diabetes Care. 2003; 26(7):2139-43. DOI: 10.2337/diacare.26.7.2139. View

Dehmer T, Heneka M, Sastre M, Dichgans J, Schulz J . Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem. 2003; 88(2):494-501. DOI: 10.1046/j.1471-4159.2003.02210.x. View

10.

Mullick A, Tobias P, Curtiss L . Modulation of atherosclerosis in mice by Toll-like receptor 2. J Clin Invest. 2005; 115(11):3149-56. PMC: 1242192. DOI: 10.1172/JCI25482. View

11.

Coll R, ONeill L . New insights into the regulation of signalling by toll-like receptors and nod-like receptors. J Innate Immun. 2010; 2(5):406-21. DOI: 10.1159/000315469. View

12.

Du T, Zhou Z, You S, Lin J, Yang L, Zhou W . Regulation by 1, 25-dihydroxy-vitamin D3 on altered TLRs expression and response to ligands of monocyte from autoimmune diabetes. Clin Chim Acta. 2009; 402(1-2):133-8. DOI: 10.1016/j.cca.2008.12.038. View

13.

Michelsen K, Wong M, Shah P, Zhang W, Yano J, Doherty T . Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci U S A. 2004; 101(29):10679-84. PMC: 489994. DOI: 10.1073/pnas.0403249101. View

14.

Du T, Zhou Z, You S, Huang G, Lin J, Yang L . Modulation of monocyte hyperresponsiveness to TLR ligands by 1,25-dihydroxy-vitamin D3 from LADA and T2DM. Diabetes Res Clin Pract. 2008; 83(2):208-14. DOI: 10.1016/j.diabres.2008.09.046. View

15.

Ji Y, Liu J, Wang Z, Liu N, Gou W . PPARgamma agonist, rosiglitazone, regulates angiotensin II-induced vascular inflammation through the TLR4-dependent signaling pathway. Lab Invest. 2009; 89(8):887-902. DOI: 10.1038/labinvest.2009.45. View

16.

Andersson U, Tracey K . HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol. 2011; 29:139-62. PMC: 4536551. DOI: 10.1146/annurev-immunol-030409-101323. View

17.

Fresno M, Alvarez R, Cuesta N . Toll-like receptors, inflammation, metabolism and obesity. Arch Physiol Biochem. 2011; 117(3):151-64. DOI: 10.3109/13813455.2011.562514. View

18.

Niessner A, Steiner S, Speidl W, Pleiner J, Seidinger D, Maurer G . Simvastatin suppresses endotoxin-induced upregulation of toll-like receptors 4 and 2 in vivo. Atherosclerosis. 2006; 189(2):408-13. DOI: 10.1016/j.atherosclerosis.2005.12.022. View

19.

Beutler B . Inferences, questions and possibilities in Toll-like receptor signalling. Nature. 2004; 430(6996):257-63. DOI: 10.1038/nature02761. View

20.

Hodgkinson C, Laxton R, Patel K, Ye S . Advanced glycation end-product of low density lipoprotein activates the toll-like 4 receptor pathway implications for diabetic atherosclerosis. Arterioscler Thromb Vasc Biol. 2008; 28(12):2275-81. DOI: 10.1161/ATVBAHA.108.175992. View